Patents by Inventor Elizabeth A. Jaffee
Elizabeth A. Jaffee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11965162Abstract: In one aspect, compositions are provided for the early diagnosis and treatment of pancreatic ductal adenocarcinoma and include microRNAs, e.g. miR-21 and inhibitors thereof. The treatment compositions can be useful for early detection, and for intercepting developing premalignant pancreatic lesions and other KRAS-driven premalignancies.Type: GrantFiled: April 16, 2021Date of Patent: April 23, 2024Assignee: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Nina Chu, Jacquelyn Winifred Zimmerman
-
Publication number: 20230173049Abstract: The invention features compositions and methods for treating and preventing cancer. In one aspect, isolated fusion proteins are provided that comprise a DNAJBI portion and a PRKACA portion. In a further aspect, compositions are provided, including immunogenic compositions that comprise an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion. In a yet further aspect, a cancer vaccine is provided that comprises an isolated fusion protein comprising a DNAJBI portion and a PRKACA portion.Type: ApplicationFiled: December 31, 2020Publication date: June 8, 2023Inventors: Mark Yarchoan, Elizabeth Jaffee, Aditya Mohan
-
Publication number: 20220267274Abstract: Described are methods of treating solid cancers in a subject. The methods comprise the steps of administering to the subject having the solid cancer or prone of getting the solid cancer an antagonist of PTPN22, or the functional part of PTPN22, and treating the solid cancer. Methods comprising use of other anticancer agents and adjuvants in conjunction with PTPN22 inhibitors are also provided.Type: ApplicationFiled: July 10, 2020Publication date: August 25, 2022Inventors: Elizabeth Jaffee, Won Jin Ho
-
Publication number: 20220133788Abstract: Anti-tumor immune response are generated by induction of activated B cells to provide costimulatory signals necessary for T cell activation. Certain compositions are combined with anti-immune checkpoint inhibitors to generate a synergistic anti-tumor response.Type: ApplicationFiled: December 19, 2018Publication date: May 5, 2022Inventors: Elizabeth A. Jaffee, Mark Yarchoan
-
Patent number: 11285197Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: July 2, 2019Date of Patent: March 29, 2022Assignee: Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Publication number: 20210324383Abstract: In one aspect, compositions are provided for the early diagnosis and treatment of pancreatic ductal adenocarcinoma and include microRNAs, e.g. miR-21 and inhibitors thereof. The treatment compositions can be useful for early detection, and for intercepting developing premalignant pancreatic lesions and other KRAS-driven premalignancies.Type: ApplicationFiled: April 16, 2021Publication date: October 21, 2021Inventors: Elizabeth A. Jaffee, Nina Chu, Jacquelyn Winifred Zimmerman
-
Publication number: 20200093911Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: ApplicationFiled: July 2, 2019Publication date: March 26, 2020Applicant: Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Patent number: 10350282Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: October 25, 2016Date of Patent: July 16, 2019Assignee: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Patent number: 10048266Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.Type: GrantFiled: November 10, 2017Date of Patent: August 14, 2018Assignee: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Darshil T. Jhaveri, Robert Anders
-
Publication number: 20180120322Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.Type: ApplicationFiled: November 10, 2017Publication date: May 3, 2018Inventors: Elizabeth A. Jaffee, Darshil T. Jhaveri, Robert Anders
-
Publication number: 20170106067Abstract: The invention features compositions and methods for treating and preventing pancreatic cancer.Type: ApplicationFiled: June 12, 2015Publication date: April 20, 2017Inventors: Elizabeth Jaffee, Lei Zheng
-
Publication number: 20170072040Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: ApplicationFiled: October 25, 2016Publication date: March 16, 2017Applicant: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Publication number: 20160327560Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Inventors: Elizabeth A. Jaffee, Darshil T. Jhaveri, Robert Anders
-
Publication number: 20160199473Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: ApplicationFiled: March 14, 2016Publication date: July 14, 2016Applicant: The Johns Hopkins UniversityInventors: Elizabeth A. Jaffee, Ralph Hruban
-
Patent number: 9296784Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: October 1, 2013Date of Patent: March 29, 2016Assignee: The Johns Hopkins UniversityInventors: Elizabeth Jaffee, Ralph Hruban
-
Patent number: 9200036Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: November 10, 2011Date of Patent: December 1, 2015Assignee: The Johns Hopkins UniversityInventors: Elizabeth Jaffee, Ralph Hruban
-
Publication number: 20150316554Abstract: We identified >40 proteins that elicited at least a 2-fold increase in antibody response post-pancreatic-cancer vaccination, from each of three patients' sera. The antibody responses detected against these proteins in patients with >3 years disease-free survival indicates the anti-tumor potential of targeting these proteins. We found that tissue expression of proteins PSMC5, TFRC and PPP1R12A increases during tumor development from normal to pre-malignant to pancreatic tumor. In addition, these proteins were shown to be pancreatic cancer-associated antigens that are recognized by post-vaccination antibodies in the sera of patients that received the vaccine and have demonstrated a favorable disease free survival.Type: ApplicationFiled: December 2, 2013Publication date: November 5, 2015Inventors: Elizabeth A. Jaffee, Darshil T. Jhaveri, Robert Anders
-
Publication number: 20140050751Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: ApplicationFiled: October 1, 2013Publication date: February 20, 2014Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Elizabeth Jaffee, Tzyy-Choou Wu, Chien-Fu Hung, Ralph Hruban
-
Publication number: 20120076752Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: ApplicationFiled: November 10, 2011Publication date: March 29, 2012Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Tzyy-Choou WU, Chien-Fu Hung, Elizabeth JAFFEE, Ralph HRUBAN
-
Patent number: 8137908Abstract: Mesothelin can be used as an immunotherapeutic target. It induces a cytolytic T cell response. Portions of mesothelin which induce such responses are identified. Vaccines can be either polynucleotide- or polypeptide-based. Carriers for raising a cytolytic T cell response include bacteria and viruses. A mouse model for testing vaccines and other anti-tumor therapeutics and prophylactics comprises a strongly mesothelin-expressing, transformed peritoneal cell line.Type: GrantFiled: September 15, 2008Date of Patent: March 20, 2012Assignee: The Johns Hopkins UniversityInventors: Elizabeth Jaffee, Ralph Hruban